AbbVie to replace Dell on S&P 100; LegitScript says it killed off MyRxCash.com; Halozyme, Pfizer collaborate;

@FiercePharma: Smaller players looking for expansion deals, too. News | Follow @FiercePharma

> Abbott Laboratories ($ABT) spinoff AbbVie is not yet a company but it is set to land on two Standard & Poor's stock indices, replacing Federated Investors in the S&P 500 and computer maker Dell on the S&P 100. Story

> Halozyme Therapeutics ($HALO) says it has landed a deal to work with Pfizer ($PFE) to develop up to 6 injectable medicines with its process of using human enzymes to modify drugs so they can be injected. Story

> LegitScript, which contracts with search engines and Internet domain-name providers to ferret out advertising and hosting services, says its efforts have taken down MyRxCash.com, a portal it said linked hundreds of online pharmacies selling unapproved drugs. Item

> A former Pfizer employee has sued saying she was fired for violating the company's conflict of interest policy after being forced into a sexual relationship by her manager. Story

> Purdue Pharma, maker of OxyContin, has chipped in a $2,500 reward for information leading to the arrest of the person responsible for a pharmacy burglary in Fenton, MI. Story

> The Pakistan Pharmaceutical Manufacturers Association (PPMA) said drugmakers in Lahore will go on strike Monday to protest the handling of several deaths that the PPMA said the government erroneously blamed on poor cough syrup manufacturing. Story

Medical Device News

 @FierceMedDev: St. Jude faces escalation of shareholder lawsuits over Durata leads. Article | Follow @FierceMedDev

@MarkHFierce: Nanostim says it successfully implanted leadless cardiac pacers into 11 patients in the Czech Republic. Major progress. News | Follow @MarkHFierce

 @DamianFierce:  Critical Diagnostics has inked distribution deals for its heart test with Quest ($DGX) and LabCorp ($LH). More | Follow @DamianFierce

> Invacare unloads med supplies unit to AssuraMed for $150M. Story

> Cincinnati Children's/Ben-Gurion U back 3 pediatric device projects. Item

> Illumina soars on fresh Roche buyout rumors. Report

Biotech News

 @FierceBiotech: Add a drop of blood, and this tiny Dx device tests 50 things at once. Story | Follow @FierceBiotech

@JohnCFierce: Halozyme gets $8M upfront and a bunch of potential biobucks in drug delivery collab with Pfizer. Release | Follow @JohnCFierce

@RyanMFierce: Halozyme rebounds with $8M Pfizer biologics pact. More | Follow @RyanMFierce

> Transcept caps a tough year with PhII drug failure. Article

> Merck's big PhIII failure on cholesterol drug spurs an EMA review. Report

> Raptor gets $50M loan to back launch of rare disease drug. News

> Karolinska Development inks a $33M deal on a batch of its projects. Story

And Finally... Some women Dartmouth College students have produced a video intended to counter the one released last summer by the European Commission called "Science, Its a Girl Thing," which was intended to entice females to the business but was lambasted for leaning on stereotypes like girls in short skirts and lipstick to make its point. Story

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.